Renal toxicities of novel agents used for treatment of multiple myeloma

Rimda Wanchoo; Ala Abudayyeh; Mona Doshi; Amaka Edeani; Ilya G. Glezerman; Divya Monga; Mitchell Rosner; Kenar D. Jhaveri

doi:10.2215/CJN.06100616

Renal toxicities of novel agents used for treatment of multiple myeloma

Rimda Wanchoo, Ala Abudayyeh, Mona Doshi, Amaka Edeani, Ilya G. Glezerman, Divya Monga, Mitchell Rosner, Kenar D. Jhaveri

Research output: Contribution to journal › Review article › peer-review

34 Scopus citations

Abstract

Survival for patients with multiple myeloma has significantly improved in the last decade in large part due to the development of proteasome inhibitors and immunomodulatory drugs. These next generation agents with novel mechanisms of action as well as targeted therapies are being used both in the preclinical and clinical settings for patients with myeloma. These agents include monoclonal antibodies, deacetylase inhibitors, kinase inhibitors, agents affecting various signaling pathways, immune check point inhibitors, and other targeted therapies. In some cases, off target effects of these therapies can lead to unanticipated effects on the kidney that can range from electrolyte disorders to AKI. In this review, we discuss the nephrotoxicities of novel agents currently in practice as well as in development for the treatment of myeloma.

Original language	English (US)
Pages (from-to)	176-189
Number of pages	14
Journal	Clinical Journal of the American Society of Nephrology
Volume	12
Issue number	1
DOIs	https://doi.org/10.2215/CJN.06100616
State	Published - Jan 6 2017
Externally published	Yes

ASJC Scopus subject areas

Epidemiology
Critical Care and Intensive Care Medicine
Nephrology
Transplantation

Access to Document

10.2215/CJN.06100616

Cite this

@article{5971f2d728114470880b696dc07634a6,

title = "Renal toxicities of novel agents used for treatment of multiple myeloma",

abstract = "Survival for patients with multiple myeloma has significantly improved in the last decade in large part due to the development of proteasome inhibitors and immunomodulatory drugs. These next generation agents with novel mechanisms of action as well as targeted therapies are being used both in the preclinical and clinical settings for patients with myeloma. These agents include monoclonal antibodies, deacetylase inhibitors, kinase inhibitors, agents affecting various signaling pathways, immune check point inhibitors, and other targeted therapies. In some cases, off target effects of these therapies can lead to unanticipated effects on the kidney that can range from electrolyte disorders to AKI. In this review, we discuss the nephrotoxicities of novel agents currently in practice as well as in development for the treatment of myeloma.",

author = "Rimda Wanchoo and Ala Abudayyeh and Mona Doshi and Amaka Edeani and Glezerman, {Ilya G.} and Divya Monga and Mitchell Rosner and Jhaveri, {Kenar D.}",

note = "Publisher Copyright: {\textcopyright} 2016 by the American Society of Nephrology.",

year = "2017",

month = jan,

day = "6",

doi = "10.2215/CJN.06100616",

language = "English (US)",

volume = "12",

pages = "176--189",

journal = "Clinical journal of the American Society of Nephrology : CJASN",

issn = "1555-9041",

publisher = "American Society of Nephrology",

number = "1",

}

TY - JOUR

T1 - Renal toxicities of novel agents used for treatment of multiple myeloma

AU - Wanchoo, Rimda

AU - Abudayyeh, Ala

AU - Doshi, Mona

AU - Edeani, Amaka

AU - Glezerman, Ilya G.

AU - Monga, Divya

AU - Rosner, Mitchell

AU - Jhaveri, Kenar D.

PY - 2017/1/6

Y1 - 2017/1/6

N2 - Survival for patients with multiple myeloma has significantly improved in the last decade in large part due to the development of proteasome inhibitors and immunomodulatory drugs. These next generation agents with novel mechanisms of action as well as targeted therapies are being used both in the preclinical and clinical settings for patients with myeloma. These agents include monoclonal antibodies, deacetylase inhibitors, kinase inhibitors, agents affecting various signaling pathways, immune check point inhibitors, and other targeted therapies. In some cases, off target effects of these therapies can lead to unanticipated effects on the kidney that can range from electrolyte disorders to AKI. In this review, we discuss the nephrotoxicities of novel agents currently in practice as well as in development for the treatment of myeloma.

AB - Survival for patients with multiple myeloma has significantly improved in the last decade in large part due to the development of proteasome inhibitors and immunomodulatory drugs. These next generation agents with novel mechanisms of action as well as targeted therapies are being used both in the preclinical and clinical settings for patients with myeloma. These agents include monoclonal antibodies, deacetylase inhibitors, kinase inhibitors, agents affecting various signaling pathways, immune check point inhibitors, and other targeted therapies. In some cases, off target effects of these therapies can lead to unanticipated effects on the kidney that can range from electrolyte disorders to AKI. In this review, we discuss the nephrotoxicities of novel agents currently in practice as well as in development for the treatment of myeloma.

UR - http://www.scopus.com/inward/record.url?scp=85014842412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014842412&partnerID=8YFLogxK

U2 - 10.2215/CJN.06100616

DO - 10.2215/CJN.06100616

M3 - Review article

C2 - 27654928

AN - SCOPUS:85014842412

SN - 1555-9041

VL - 12

SP - 176

EP - 189

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

IS - 1

ER -

Renal toxicities of novel agents used for treatment of multiple myeloma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this